A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer…

Overview of attention for article published in BMC Cancer, August 2011

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 68 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,157 followers.

Phase III Trial: Capecitabine + Bevacizumab vs Capecitabine + Irinotecan + Bevacizumab Metastatic #Colorectal Cancer http://t.co/2DuANOR

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.